Skip to content
EntityQ782318· pop 13· linked from 301 articles

verteporfin

Sign in to save

Also known as BPD952, CL-318952

Verteporfin (trade name Visudyne), a benzoporphyrin derivative, is a medication used as a photosensitizer for photodynamic therapy to eliminate the abnormal blood vessels in the eye associated with conditions such as the wet form of macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 689 nm in the presence of oxygen, produces highly reactive short-lived singlet oxygen and other reactive oxygen radicals, resulting in local damage to the endothelium and blockage of the vessels.

Key facts

Drug.Verifiedfields
changed
Drug.verifiedrevid
470629762
Drug.IUPAC_name
3-[(23S,24R)-14-ethenyl-5-(3-methoxy-3-oxopropyl)-22,23-bis(methoxycarbonyl)-4,10,15,24-tetramethyl-25,26,27,28-tetraazahexacyclo[16.6.1.13,6.18,11.113,16.019,24]octacosa-1,3,5,7,9,11(27),12,14,16,18(25),19,21-dodecaen-9-yl]propanoic acid
Drug.image
Verteporfin.svg
Drug.image_class
skin-invert-image
Drug.tradename
Visudyne
Drug.MedlinePlus
a607060
Drug.pregnancy_US
C
Drug.licence_EU
yes
Drug.legal_US
Rx-only
Drug.routes_of_administration
Intravenous
Drug.CAS_number
129497–78–5
Drug.ATC_prefix
S01
Drug.ATC_suffix
LA01
Drug.PubChem
5362420
Drug.DrugBank
DB00460
Drug.ChemSpiderID
21106402
Drug.UNII
0X9PA28K43

via Wikipedia infobox

Wikidata facts

Mass
2875.2
Show 3 more facts
World Health Organisation international non-proprietary name
verteporfin
NCI Thesaurus ID
C1014
chemical formula
C₁₆₄H₁₆₈N₁₆O₃₂
Sources (3)

via Wikidata · CC0

~3 min read

Article

9 sections
Contents
  • Administration
  • Contraindications
  • Side effects
  • Light-activated cytotoxicity
  • Interactions
  • Shortages
  • Off-label use
  • References
  • External links

Verteporfin (trade name Visudyne), a benzoporphyrin derivative, is a medication used as a photosensitizer for photodynamic therapy to eliminate the abnormal blood vessels in the eye associated with conditions such as the wet form of macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 689 nm in the presence of oxygen, produces highly reactive short-lived singlet oxygen and other reactive oxygen radicals, resulting in local damage to the endothelium and blockage of the vessels.

Verteporfin is also used off-label for the treatment of central serous retinopathy.

Connections

Categories